Cognito Therapeutics secures $105 million in Series C funding led by Morningside Ventures to advance Spectris™ in Alzheimer’s disease.
Amount Raised
$105 Million
Round Type
Series C
CambridgeManufacturingHealthcareHealth CareInvestors
Description
Cognito Therapeutics has announced the close of its oversubscribed $105 million Series C funding. The financing will support pivotal study data readout, FDA submission, and commercialization in Alzheimer's disease by 2027. The round was led by Morningside Ventures, IAG Capital Partners, and Starbloom Capital. This funding will also aid in advancing additional neurodegenerative indications through their network of brain health collaboratories.
Who to call at Cognito Therapeutics, and when
A new round usually means Cognito Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Cognito Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Cognito Therapeutics, from your own LinkedIn network
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Cognito Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Cognito Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.